Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drugresistant bacterial infections, announces today that the U.S Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate AAI101 when given in fixed dose combination with the antibiotic cefepime, a powerful treatment for serious hospital-acquired Infections.
Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections
Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf
Topas Therapeutics GmbH (Topas), today announced that it will serve as the exclusive translational partner for the recently extended Collaborative Research Center (CRC) 841, “Liver inflammation: infection, immune regulation and consequences.” CRC 841 has 25 sub-projects investigating the causes and mechanisms of inflammatory liver diseases, laying the groundwork for new therapeutic approaches.
Immatics Proprietary Target Selected for the Development of Cancer Immunotherapies
Immatics, a leading company in the field of cancer immunotherapy, announced today that Roche has exercised its option under the existing discovery, development and commercialization agreement between the companies to exclusively license from Immatics a proprietary immunotherapy target for further development and commercialization in oncology.